CTOS 2017

Researchers attempted to determine factors associated with DSS after patients with metastatic disease undergo surgical resection.

Researchers presented olaratumab monotherapy subgroup results from a phase 2 trial of patients who were previously treated with olaratumab plus doxorubicin or doxorubicin alone.

Just over half of patients in a standard therapy group had normal bone mineral density after a mean follow-up of 6 years; this contrasted with 93% of patients in a vitamin D supplementation group.

As the disease’s location can make localized treatment difficult, factors that predict for LR and OS may be helpful for treatment decision-making.

No significant association between GPNBM levels and disease response was found. Due to futility, the researchers did not pursue a second stage of the trial.

Researchers are evaluating whether BLU-285, which is active regardless of resistance-associated mutations, is safe and effective among patients with an imatinib-resistant GIST.

Researchers enrolled 11 patients with infantile fibrosarcoma or another sarcoma subtype to receive larotrectinib followed by surgery.

In a randomized phase 2 trial, CASPS, researchers enrolled 48 patients with metastatic ASPS that progressed within the preceding 6 months. The primary endpoint was change in tumor size.